# Simeon George

> Simeon J. George is the founder and CEO of SR One, the venture capital firm he co-founded as an independent business following its 2020 spinout from GSK. He joined SR One in 2007, led investments in companies including CRISPR Therapeutics, Principia Biopharma and Turning Point Therapeutics, and co-founded Nkarta and Arcellx. His education spans Johns Hopkins, the University of Pennsylvania and Wharton, and his earlier career included Bain & Company and Goldman Sachs.

- **Role:** Founder and CEO at SR One
- **Organizations:** SR One Capital Management, GSK, Bain & Company, Goldman Sachs, Nkarta, Arcellx, CRISPR Therapeutics, ADARx Pharmaceuticals, Design Therapeutics
- **Nationality:** American
- **Education:** BA, Johns Hopkins University, MD, University of Pennsylvania School of Medicine, MBA, The Wharton School, University of Pennsylvania
- **Known for:** Co-founded independent SR One following its 2020 spinout from GSK., Led the firm through its first two independent fund closings: $500 million in 2020 and over $600 million in 2023., Co-founded Nkarta and Arcellx.

## Career timeline

- **Before 2007** — Worked in investment banking at Goldman Sachs and management consulting at Bain & Company.
- **2007** — Joined SR One.
- **2018** — Became CEO of GSK’s SR One in January, according to Design Therapeutics’ proxy biography.
- **2020** — Co-founded independent SR One Capital Management following the GSK spinout; the first independent fund closed at $500 million.
- **2021** — Joined the ADARx board in July.
- **2023** — SR One announced its second independent venture fund at over $600 million; George became Design Therapeutics’ lead independent director in August.
- **2026** — Discussed the firm’s evolution and investing approach in BioHub, BioVenture VoiCes and Bloomberg Intelligence interviews.

## Achievements

- Co-founded independent SR One following its 2020 spinout from GSK.
- Led the firm through its first two independent fund closings: $500 million in 2020 and over $600 million in 2023.
- Co-founded Nkarta and Arcellx.
- Led SR One investments in CRISPR Therapeutics, Principia Biopharma, Turning Point Therapeutics and Progyny.

## Latest updates

- **2026-02** — Appeared on The BioHub, episode 115, released February 10.
- **2026-03** — Featured in BioVenture VoiCes episode 37, discussing SR One’s independence and peer-to-peer collaboration.
- **2026-05** — Discussed global competition and milestone-focused venture financing in a May 26 BioPharma Dive interview.
- **2026-07** — Appeared on Bloomberg Intelligence’s Vanguards podcast on July 16 to discuss SR One’s evolution and investment outlook.

## Links

- Website: https://www.srone.com/team/simeon-george
- LinkedIn: https://www.linkedin.com/in/simeon-george-b2707985

---

Profile page: https://yespress.io/simeon-george
Published by YesPress — https://yespress.io
Last updated: 2026-10-09